SIRPA and neoplasm: CD47 monoclonal antibody (aCD47) can prevent the binding of CD47 and SIRPα, thereby promoting tumor cell phagocytosis by TAMs and DCs [20,21]; however, many challenges remain to be overcome in application of aCD47 in osteosarcoma, including low immune response rates and systemic side effects.